EMA — authorised 19 September 2019
- Marketing authorisation holder: Acorda Therapeutics Ireland Limited
- Status: approved
🇪🇺 Inbrija in European Union
EMA authorised Inbrija on 19 September 2019
Marketing authorisations
EMA — authorised 19 September 2019
- Application: EMEA/H/C/004786
- Marketing authorisation holder: Merz Therapeutics GmbH
- Local brand name: Inbrija
- Indication: Inbrija is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor.
- Status: approved
Inbrija in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Neuroscience approved in European Union
Frequently asked questions
Is Inbrija approved in European Union?
Yes. EMA authorised it on 19 September 2019; EMA authorised it on 19 September 2019.
Who is the marketing authorisation holder for Inbrija in European Union?
Acorda Therapeutics Ireland Limited holds the EU marketing authorisation.